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Abstract 
Background: 
Assess early oncological and functional outcomes following radical treatment of men with high risk 
prostate cancer and aged more than 70 years.  
Patients and Methods: 
335 men with high risk prostate cancer (PSA ≥20 ng/ml or biopsy Gleason score 8–10 or ≥cT2c) 
received radical treatment between 2007 and 2014. Men were identified from comprehensive 
clinical databases hosted at a tertiary cancer centre in the UK. The data included basic 
demographics, and follow-up on functional and oncological outcomes using validated patient 
reported outcome questionnaires.  Univariate and multivariate analyses were performed in SPSS 
version 21. 
Results: 
117 patients received radical radiotherapy alone, 167 received neo-adjuvant hormone therapy and 
radiotherapy, and 54 radical prostatectomy with extended lymph node dissection. Mean age was 
72.8, SD 2.1 with a mean follow-up of 40.9 months, SD 25.5 months.  Of the patients who underwent 
LRP 24 (44.4%) had positive surgical margins, mean lymph nodes dissected were 18.7, SD 6.7 (min 15 
and max 33).  Five men experience post-operative complications in the form of pseudoaneurism of 
internal iliac branch, leg ischemia, high Co2 retention, and two men experienced sepsis.   Incidence 
of biochemical recurrence was significantly lower 16.7% in the surgery group, compared to RT 51.3% 
and RT and HT 30.5%, Kaplan-Meier analysis P<0.001 over 3 years of follow-up 
Conclusion 
Radical surgery with extended lymph nodes dissection appears to have good short-term oncological 
and functional outcomes compared to radiotherapy with or without hormones in high risk men over 
70 years.  Based on these findings treatment decisions should be individualised and after considering 
the health status of each patient.  
Introduction 
Prostate cancer remains the most common malignancy among elderly men and is the second leading 
malignancy in the Western World [5] with steadily increasing incidence over the last decade.  
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Between 2000 and 2050, the number of elderly men affected by prostate cancer is expected to 
increase 4-fold worldwide [5]. All this leads to a healthcare challenge in terms of radical treatment, 
in particular surgery in elderly men with good performance status.   Current practice of radical 
treatment for localized prostate cancer is guided by expert guidelines,  recommending potentially 
curative therapy for whose with life expectancy of at least 10 years [1, 2].  Guidelines also stipulate 
men with limited life expectancy are more likely to die from health conditions other than prostate 
cancer, and are best managed conservatively as radical treatment may impair their quality of life. 
This approach may deprive survival advantage in men older than 70 years, especially with good 
performance status [3].  This is increasingly realized in the presence of minimally invasive surgery 
(laparoscopic prostatectomy [LRP], with or without assistance of robot), with demonstrated 
improved perioperative morbidity and outcomes [4].   Thus, accepted 10-year rule- a common 
practice among urologists and radiation oncologists may need a re-visiting [6, 7].  However, aging is a 
highly individualized, multidimensional process where chronologic age does not always predict the 
physiologic decline in an individual because, in part, of the effect of comorbidity [9].  Bearing this in 
mind, there is a need for an approach to extend indications of surgical treatment in selected group 
of men more than 70 years of age.    
Evidence from a recent study suggests  that in age-stratified random sample of 347 men from a 
cohort of patients with newly diagnosed prostate cancer in the Ontario Cancer Registry, several 
clinical factors can influence treatment options [6]. Patients who were younger than 60 years were 
more likely to receive radical prostatectomy than radiation therapy or no therapy. Men between 60 
and 69 years of age were more likely to receive radiation therapy than radical prostatectomy. Men 
between 70 and 79 years were most likely to receive conservative therapy such as hormone therapy, 
and nearly all men over 80 years received no therapy. The decreased likelihood of receiving curative 
therapy is correlated with patient age, Charlson index score and tumor stage [6]. 
The above observation is further supported by reported literature from others.  Older men have 
been shown to receive potentially curative therapy (radical prostatectomy or radiotherapy) less 
often than younger men. Radical prostatectomy is preferred treatment in men younger than 70 
years, whereas radiation therapy is applied predominantly in patients older than 70 years [6-8]. 
Conservative therapy such as watchful waiting or androgen deprivation by luteinizing hormone-
releasing hormone analogs is preferentially applied in men older than 80 years.  
However, a judicious decisions needs to be made considering age, clinical stage, PSA level, 
histological grade, and comorbidities.  These should be carefully balanced against the survival 
advantage before making a treatment decision [8].   
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 In our centre, we have been offering radical surgery in high risk patients (PSA  ≥ 20; Gleason score  ≥ 
8 and more, ≥cT2c disease) based on a careful assessment and discussions in tumour boards 
(multidisciplinary teams).   We aim to compare the oncological and functional outcomes in elderly 
men over 70 years diagnosed with high-risk prostate cancer treated with radical therapy (surgery 
and radiotherapy).  
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Patients and Methods 
The study had Caldecott Institutional Approval (Caldicott/CSAppGN021211). During January 2007 
and December 2014, 335 patients who underwent radical radiotherapy, neoadjuvant hormonal 
therapy and radiotherapy, or laparoscopic radical prostatectomy identified from comprehensive 
clinical databases hosted at a tertiary cancer centre in the UK.    For this study, radiotherapy with or 
without hormone included men up to December 2011 to get a meaningful follow-up of at least 3 
years for each man.  For surgery, each patient had at least one year follow-up to provide a 
meaningful early oncological and functional outcomes 
The TUCAN (Tayside Urological Cancers Network Database) collects routine data from the 
population of urological cancers in Tayside, Scotland.   NHS Tayside serves a predominantly 
Caucasian rural and urban population of more than 405,721 based on mid-year 2011 population 
estimates published by the General Register Office for Scotland.  Population is registered with health 
care board through a unique number called as Community Health Index number (CHI number) and is 
served by 75 general practices and single tertiary urological cancers services.   All newly diagnosed 
cancers are reviewed by a local multidisciplinary team and the meeting records are stored in a 
database known as the “Tayside Urological Cancer Network Database” [9].  Study data was collected 
using a validated record-linkage methodology using the CHI number as described by us previously 
[10, 11]. 
Record linkage technique brings together two or more records relating to the same individual 
identified by a common identifier (Community Health Index [CHI] number in this series). Cross-
linkage of databases enabled demographical and clinical data to be securely managed at one 
centralized database for the purpose of this study.   
The database with (CHI) was linked to the following clinical systems: 
(i)       WISDOM oncology system (Web Information System For Data Oncology Management) 
which securely stores the following clinical information: clinical presentation, PSA, 
cancer stage, Gleason score, radiotherapy, clinical complications, follow-up and 
mortality 
(ii)       Referral Management System (RMS) which is a primary care system for a population of 
more than 400,000 individuals. Data linkage captured co-morbidities        
(iii)  Multidisciplinary Board Meeting (MDT) records where all men diagnosed with prostate 
cancer are discussed on a weekly basis.   
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(iv)      Integrated Clinical Environment (ICE) system provides clinicians with diagnostic services 
as a means to electronically order tests and view results. Using the CHI number, we 
searched for sequential PSA results. 
(v)      Records were searched using Clinical Portal and the In House Surgical Information System 
web and Technology (Insite), these databases host secure electronic patient records 
which systematically captures follow-up history including communication between acute 
and primary care.  
Inclusion criteria were: (1) patients more than 70 years of age who were newly diagnosed and 
histologically confirmed localized or locally advanced adenocarcinoma of prostate; (2) patients 
suitable and those opting for primary radical radiotherapy, neoadjuvant/adjuvant hormonal therapy 
for 24 months and radiotherapy or radical prostatectomy; (3) patients ≥ age of 70 years with one of 
the following high risk factors, (PSA ≥20 ng/ml or biopsy Gleason score 8–10 or ≥cT2c). Exclusion 
criteria were: (1) Patients who would not have qualified for radical surgical treatment and 
radiotherapy with hormones was considered as the only option after multidisciplinary meeting 
discussion (this group invariably included men with PSA more than 50 or MRI showing gross 
extracapsular extension precluding any safe resection if they had opted for surgery) 2) patients with 
missing clinical data such as dose of radiotherapy, tumour stage, Gleason score, PSA or no history of 
follow-up 3) patients unable to meet the inclusion criteria. 
All LRP at our institution were performed by one surgeon (GN).  Extended pelvic lymphadenectomy 
was performed on all patients as described before [12].  All pathological RP specimens were 
reviewed by a senior Consultant Uropathologists (SL) and discussed in multidisciplinary team 
meetings to record proper staging including discussion of adjuvant treatment (radiotherapy or 
hormones) 
 
Demographic and clinical data were collected prospectively from consecutive patients and entered 
into a comprehensive electronic database such as our (Integrated Clinical Environment).  Variables 
included the following: age, PSA before treatment, PSA post-treatment, cancer stage, Gleason score, 
and co-morbidities. 
 
Oncological outcomes  
 
The primary outcome was the incidence of biochemical recurrence.  This was defined as detectable 
PSA (>0.2 ug/L) in at least 2 consecutive measurements for men treated by LRP [13]. After primary 
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radical radiotherapy or neoadjuvant hormonal treatment and radiotherapy biochemical recurrence 
was defined as a consecutive PSA increase > 2 ng/mL higher than the PSA nadir value [13].  Positive 
surgical margins and the need for adjuvant treatment were recorded.  Secondary outcomes being 
functional outcome and perioperative morbidity.  
Functional outcomes 
Radiation induced proctitis was graded according the European Organization for Research and 
Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) grading system of 
radiation proctitis [14] (Table 1). The grading classification was used by two members of the research 
team (AA and CP) to rate the severity of proctitis for each patient within the study. Inter-rater 
reliability was assessed using the Kappa statistic (Kappa=0.809 with p<0.001) and was found to have 
substantial agreement [15].  
LRP patients were given the self-administered International Consultation Incontinence 
Questionnaire (ICIQ-UI, see supplementary information for questionnaire) [16] at 3, 6, 9 and 12 
months post-surgery.  For the purpose of this study continence is defined as using no pad or a safety 
pad [17] in a 24 hour period.   
Statistical Analysis 
Data were double-entered into the Statistical Package for Social Sciences (SPSS, version 21). Pearson 
product moment correlation coefficients, paired sample t-tests, Chi-squared, Kruskal-Wallis H test, 
and Mann-Whitney U test were used.  Biochemical recurrence rates were obtained by using the 
principles of Kaplan-Meier analysis, the Log-Rank, Breslow and the Tarone-Ware tests.  Statistical 
significance was defined as p <0.05.  
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RESULTS  
Of the 338 patients, 117 were treated with radical radiotherapy alone, 167 received neo-adjuvant 
hormone therapy and radiotherapy, and 54 LRP (Table 2).  The overall mean age was 72.8 ± 2.1 with 
a mean follow-up of 40.9 months, SD 25.5 months, max 96 months.  There was a statistically 
significant difference in the mean age among the three groups F(2, 332)=6.889, p=0.001, RT 73.2, 
SD2.2, RT and HT 72.7, SD 2.0 and LRP 72.2, SD1.8, but the age ranges (70 -77 years) were the same 
for all three treatment groups.  The distribution of clinical characteristics across the treatment 
modalities are detailed in Table 2.  In particular RT <T3 was found in 88, 29 ≥T3, Gleason 6 (31), 
Gleason 7 (47), Gleason 8-10 (39); RT and HT <T3 (78) and ≥T3 (89), Gleason 6 (22), Gleason 7 (32) 
and Gleason 8-10 (113), and LRP cT3 (47) and >T3 (7), Gleason 6 (8), Gleason 7 (8) and Gleason 8-10 
(38).  There was no statistically significant difference in the mean PSA levels before radical treatment 
across the treatment modalities in the cohort.  
Of the patients who underwent LRP 24 (44.4%) had positive surgical margins, 39 (76.5%) has 
extended PLND with mean of 18.7, SD 6.7 (min 15 and max 33) lymph nodes, see Table 3.  Remaining 
had limited lymph node dissection.  Two men had positive nodal disease and required hormonal 
treatment.  PSA remain undetectable in both the men.   Seven men required salvage radiotherapy 
following surgery and biochemical recurrences.  Four of these have undetectable PSA at last follow-
up.  Five men experience post-operative complications in the form of pseudoaneurysm of the 
internal iliac artery (Figure 1), leg ischemia, high Co2 retention, and two men experienced sepsis.  
The majority of men stayed in hospital for two nights post LRP and 91% of men were continent by 12 
months post-surgery.  Two patients had rectal injury; which was identified and repaired during the 
surgery (histopathology of one patient with rectal mucosa removed with the prostatic specimen, see 
Figure 2).  Following RT alone 47 (40.2%) of men did not experience proctitis, Grade 1 was reported 
in 53 (45.3%), and ≥Grade 2 14 (14.6%). For those men treated by HT and RT 68 (40.7%) did not 
report proctitis, Grade 1 66 (39.5%) and ≥Grade 2 33 (19.8%). 
There was a significant difference in the PSA level between the treatment modalities H(2)  = 116.6 , 
p<.001.   A bonferroni correction was applied and so all effects are reported at a .0167 level of 
significance.  PSA levels following radical treatment was significantly lower for men treated by LRP (U 
= 39.5, p<.000) when compared to RT and RT and HT.  However, PSA levels following radical 
treatment was significantly lower for men treated with RT and HT (U = 8575, p= .011) compared to 
RT alone, see Figure 3.  The results from the cox proportional hazard analyses χ2(6) = 833.7, p < .003, 
identified the following factors to have a beneficial association with biochemical recurrence 
following radical treatment in men over 70 years old: baseline age (.917  p=.029), Gleason score 6 
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(.357, p=.005), Gleason score 7 (.584, p=.0.31), however radiotherapy alone (1.977, p=.007) 
demonstrated negative association with the incidence of biochemical recurrence in this patient 
population, see Table 2. 
The log rank test was performed to determine if there were differences in the biochemical 
recurrence distribution among the three groups: RT, RT and HT and LRP modalities.  The biochemical 
recurrence distributions for the three groups were statistically significantly different, χ 2(2) = 21.567, 
p=0.000 (Figure 2). 
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Discussion 
The current study set out to compare the early oncological and functional outcomes in elderly men 
over 70 years diagnosed with high-risk prostate cancer treated with radical therapy.  This study has 
several important findings.  First, LRP with extended lymph node dissection is feasible and 
acceptable in elderly (≥70years) men with high risk prostate cancer.  Evidence acknowledges that 
elderly men opting for LRP are more likely to have high risk tumour and advanced pathological 
stages, thus justifying a more aggressive approach in this patient population [18].   Those with 
biochemical recurrences could potentially be offered salvage treatment options, although numbers 
are small.  
In contemporary practice, however, few men aged 70 years or older undergo curative therapy for 
high-risk prostate cancer.  Compared with observation alone, curative treatment (surgery or 
radiation therapy) has been shown to improve survival in men aged 65–80 years with low- or 
intermediate-risk prostate cancer (Gleason score <7) [19].  However, in their retrospective series 
high-risk patients were not included in the analysis but data acknowledges that men older than 70 
years may benefit from curative therapy who have high risk  disease prostate cancer [18]. 
In high-risk prostate cancer, radical prostatectomy has been effective in oncological control. A large 
number of patients are cured with surgery alone. Data from a study of biochemical recurrence-free 
survival showed that 40% of patients had no evidence of disease 10 years after surgery for high-risk 
cancer [20, 21]. To date, we don’t have trial data comparing radical prostatectomy with radiation 
therapy, so no formal conclusions can be drawn, or indeed the overall benefits for senior men over 
70 years with high risk prostate cancer remains little known [22]. But here, we present the first study 
which compares the incidence of biochemical recurrence across three treatment modalities in high 
risk prostate cancer in older men.  Our findings identify the overall incidence of biochemical 
recurrence was low 16.7% in the LRP group, compared to RT 51.3% and RT and HT 30.5%, Kaplan-
Meier analysis P<0.000 over a 3 years of follow-up.  Follow-up, however remains short and it would 
be interesting to find out long-term outcome of this cohort.   
Radiotherapy is standard treatment for localised prostate cancer and is often combined with 
hormone treatment to prevent androgen stimulation of prostate cancer. Hormone therapy carries 
significant morbidity [23] and can only be justified in the radical treatment of localized disease if it 
can be balanced against a significant gain in disease control and survival.  A recent systematic review 
[24] outlines evidence that the use of combined treatment of androgen deprivation therapy and 
radiotherapy for intermediate and high-risk localised and locally advanced prostate cancer. 
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Noteworthy, the patients in our series who underwent RT treatment alone had the underpinning 
clinical rationale for this practice as the evidence to support the usage of combination of HT and RT 
was still in its infancy, at that time.  However, our findings are in keeping with favorable outcome 
following the usage of combination HT and RT versus RT alone, based on the findings of the 
incidence biochemical recurrence over time [24].  In clinical practice the optimal timing, duration, 
formulation and the management of side-effects of combination HT and RT remain important 
questions for further research [24] 
We acknowledge that using the ICIQ-UI evaluation is the gold standard for evaluating patient’s 
health status [25] and controlling for variations in surgical ability and skill [26] was a strength to this 
study’s methodology.  The mean duration of hospital stay was 2 days (1-35 days) and similar to other 
centres [27, 28].   Using the continence definition of 0-1 pads our data showed that LRP can offer 
good functional outcome with approximately 91% of men returning to baseline continence function 
by 12 months, and this is similar to data published elsewhere  [29].  In contrast, in a prospective 
study of LRP at 1 year identified that only 60% of men were continent [26].  
The primary goal of radical prostatectomy is cancer control or eradication for patient survival. 
Prediction of LRP long-term oncological outcomes are linked to many established clinical factors: 
preoperative prostate specific antigen (PSA), clinical and pathologic staging, Gleason grade, seminal 
vesicle invasion, lymph node invasion, and positive surgical margins [30]. Our study has 
demonstrated good oncological outcome in this patient group with 84.8% biochemical recurrence-
free survival at 37 months comparable with existing data [31].   
The single-surgeon design is advantageous to the study methodology as all of the patients received 
the same postoperative care and counselling. This allowed for a more critical comparison of 
oncological and functional outcomes following LRP over time.  Furthermore, the data in our study 
was gathered prospectively by third party and assessed without involvement of surgeon to avoid 
recall and reporting bias.  A further strength to this study was the use of a validated standardised 
questionnaire, the ICIQ-UI, where by other available studies have used interviews or non-validated 
questionnaires [32, 33].  There are several limitations to our prospective longitudinal observational 
study.  We did not use validated questionnaires to assess erectile dysfunction as most of these men 
opted for wide local excision in view of high risk disease or for radical radiotherapy with hormones.  
Moreover, there is a lack of randomization to treatment allocation which may introduce selection 
bias, however study represents a more of “real life” clinical practice.  Finally, we acknowledge that 
the results should be replicated in a larger sample size with a longer follow-up duration.       Despite 
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these limitations, the results provide new emergent information to inform the clinical management 
of elderly men with high risk prostate cancer.  
Conclusion 
High risk prostate cancer treated by radical surgery demonstrated improved early oncological and 
functional outcomes compared to radiotherapy with or without hormones. Radical prostatectomy 
was safe and feasible with good functional outcome, and these findings should inform future 
treatment decisions in men aged more than 70 years with high risk disease and good performance 
status.  
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Table 1: Grades of proctitis 
Grade Sign and symptoms  Overall management 
0 No symptoms  Does not require medication 
1 Minimal side effect such as urgency, occasional pain, superficial 
ulceration , < 1cm2, mild stricture and occult rectal bleeding 
Treated as outpatient and does not require lifestyle 
adjustments.  
2 Intermittent urgency and pain, superficial ulceration >1cm2, 
intermittent rectal bleeding and moderate stricture  
Treated as outpatient and requires lifestyle adjustments. 
3 Persistent urgency, pain and bleeding, deep ulceration 
associated with sever stricture  
Needs hospital admission or minor surgical intervention 
associated radical adjustment of the lifestyle  
4 Sever urgency associated with sever uncontrollable pain, sever 
bleeding, perforation, fistula and complete obstruction 
Needs hospital admission or major surgical intervention 
5 Multi-organ failure, sepsis and death Fatal side effects 
Table 2 Distribution of clinical and demographic characteristics 
Baseline Clinical and 
Demographic Variables  
RT (n117, 34.9%) RT + HT (n167, 49.9%) LRP (n54, 15.2%) p Value 
Age 
Cancer Stage 
T2a 
T2b 
T2c 
T3a 
T3b 
T4 
Gleason score 
2-6 
7 
8-10 
PSA Before Treatment 
PSA After Treatment 
Number co-morbidities 
0 
1 
2 or more co-morbidities 
73.3, SD 2.2 (min 70 max 
77) 
14 (12.0%) 
74 (63.2%) 
0 (0%) 
27 (23.1%) 
2 (1.7%) 
0 (0%) 
31 (26.5%) 
47 (40.2%) 
39 (32.5%) 
13.01, SD 6.8 (min 1.2 max 
31.9) 
2.5, SD 4.2 (min LT0.1 max 
25.4)  
69 (59.0%) 
35 (29.9%) 
13 (11.1%) 
72.7, SD 2.0 (min 70 max 77) 
10 (6%) 
0 (0%) 
68 (40.7%) 
10 (6%) 
78 (46.7%) 
1 (0.6%) 
22 (13.2%) 
32 (19.2%) 
113 (67.7%) 
12.8, SD 7.6 (min 1.3 max 
32.0) 
2.4, SD 4.0 (min LT 0.1 max 
24.2) 
100 (59.9%) 
53 (31.7%) 
14 (8.4%) 
72.2, SD 1.8, min 70 
max 77) 
10 (18.5%) 
10 (18.5%) 
27 (50%) 
7 (13%) 
0  
0 
8 (15.7%) 
8 (15.7%) 
38 (68.6%) 
10.7, SD 5.3 (min 4.5 
max 33.0) 
0.04, SD 0.1 (min 
LT0.1 – max 1.0) 
20 (37.0%) 
14 (26.0%) 
20 (37.0%) 
F(2, 335)=6.889, 
p=0.001 
X2 (2, N = 335) =26.82, 
p=0.000 
X2 (4, N = 335) =38.35, 
p=0.000 
F(2, 335)=2.140 
p=0.119 
F(2, 335)=9.030 
,p=0.000 
X2 (4, N = 335) =34.37, 
p=0.000 
Table 3 Cox proportional hazard analysis for factors that influence biochemical recurrence in men over 70 years treated by radical treatment. 
Variables  Categories P Value Hazard Ratio (95 % confidence interval)  
Age  In years  .029* . 917* .849-.991* 
Gleason Score Gleason score 6 
Gleason score 7 
.005** 
.031* 
.357** 
.584* 
.173-736** 
.358-952* 
Radical treatment Radiotherapy 
Laparoscopic radical prostatectomy 
.007** 
.520 
1.977** 
1.331 
1.203-3.249** 
.557-3.180 
Number of Co-morbid conditions Continuous .376 1.156 .839-1.593 
**Significant at the 0.01 level, * Significant at the 0.05 level 
Table 4 Clinical and functional outcomes 
Treatment modality and clinical outcomes n (%) 
Radical Surgery  
Positive surgical margins Yes 
No 
Pelvic lymph node dissection   Yes 
18.7, SD 6.7 (min 15 and max 33)  No 
Continence rates at 1 year post LRP 0-1 Pads 
2>pads 
Post-operative complications None 
Haematoma 
Leg ischemia  
High Co2 retention 
Sepsis 
Number of days in hospital Two  
Three 
Four 
Five 
>1 week 
Incidence of biochemical recurrence Yes 
No 
24 (44.4%) 
30 (55.6%) 
39 (76.5%) 
12 (23.5%) 
46 (91.0%) 
8 (9.0%) 
49 (90.7%) 
1 (1.9%) 
1 (1.9%) 
1 (1.9%) 
2 (3.7%) 
29 (53.7%) 
17 (31.5%) 
4 (7.4%) 
2 (3.7%) 
2 (3.8%) 
9 (16.7%) 
45 (83.3%) 
RT 
Grade of proctitis Grade 0 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Incidence of biochemical recurrence Yes 
No 
47(40.2%) 
53 (45.3%) 
11 (11.1%) 
2 (2.6%) 
1 (.9%) 
60 (51.3%) 
57 (48.7%) 
RT and HT 
Grade of proctitis Grade 0 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Incidence of biochemical recurrence Yes 
No 
68 (40.7%) 
66 (39.5%) 
23 (13.8) 
7 (4.2%) 
3 (1.8%) 
51 (30.5%) 
116 (69.5%) 
